The emergence and spread of multidrug resistant (MDR) and extensively drug-resistant tuberculosis (XDR) has raised public health concern about global control of TB. Our objective was to estimate the incidence of XDR-TB as compared to susceptible controls from TB patients in Tehran-Iran between 2006 and 2009.Sputum culture and drug susceptibility testing (DST) was done for patients with known or suspected TB. The strains that were identified as MDR were subjected to susceptibility testing for second-line drugs. Of 1126 culture-positive cases with first line drug susceptibility test, 91(8.08%) were Non-tuberculosis (Atypical) isolates, 8(0.7%) M. bovis and 1027(91.2%) M. tuberculosis. We detected MDR-TB in 26 patients (2.5%), of whom 2(7.7%) had XDR-TB. One of the XDR-TB patients with positive HIV infection died. This study cannot give an indication of XDR-TB rates in Iran. However, the results of this study document the existence of XDR-TB in Iran and indicate a need for surveillance data to define the magnitude and trends of this serious, contagious disease.
INTRODUCTION
Tuberculosis (TB) remains a grave burden to public health. Approximately two billion people world-wide are infected with mycobacterium tuberculosis, the pathogen responsible for tuberculosis which kills 1.7 million people each year (World Health Organization, 2006a) . Multi drug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) have emerged as significant threats to global tuberculosis (TB) control. The magnitude of the problem is evidenced from the forth global report of the world health organization (WHO) which reported data from 81 countries across the globe (Sharma et al., 2009) . It is estimated that 489,139 cases emerged in 2006, and the global proportion of resistance among all incident TB cases was 4.8%. China and India are estimated to carry 50% of the global burden, with the *Corresponding author. E-mail: tbchemistry@yahoo.com. Tel: +982166968853.
Russian Federation carrying a further 7% (World Health Organization, 2008) . The high proportion of XDR-TB among MDR-TB, ranging from 4.0% to over 20% as well as the large underlying burden of MDR-TB suggests that XDR-TB is more expensive and difficult to treat than MDR-TB and outcomes for patients are much worse (Jeon et al., 2008; Cox et al., 2007) , therefore understanding the magnitude and distribution of XDR-TB is important (World Health Organization, 2008) .
The emergence of XDR-TB, coupled with increased use of second-line drugs, suggests that urgent measures are needed to establish population-based surveillance for second-line drug resistance and to plan public responses (Wkly Rep, 2006) . Extensively drug resistant TB, XDR-TB is resistant to first line agents (Isoniazid and Rifampicin), as well as to at least one fluoroquinolone and at least one inject able agent (Wkly Epid, 2006) . The exact prevalence of XDR-TB in most regions of the world is currently unknown. For this reason, we set out a retrospective survey to determine the incidence of 1 MDR-TB is defined as resistance to isoniazid and rifampicin. 2 XDR-TB is defined as resistance to rifampicin and asoniazid. In addition to any fluroquinolone and to at least one of the three following inject able drugs: capreomycin, kanamycin and amikacin.
XDR-TB among MDR patients who refer to TB lab of Mycobacteriology Department of Pasteur Institute of Iran between 2006 and 2009. Therefore, we retrospectively reviewed these cases and compared them to controls with susceptible disease.
MATERIALS AND METHODS

Setting and study population
We did this study in the 
Digestion-decontamination procedures
Digestion and decontamination was done with the N-acetyl-Lcysteine-sodium hydroxide method (Kent and Kubica, 1985) . Cultures were done on Lowenstein-Jensen (LJ) slopes by the standard procedures manual of CDC. Acid fast microscopy, to confirm the presence of acid-fast bacilli, was done on each sputum samples. All positive cultures were identified as M. tuberculosis by means of Niacin test, Catalase activity, Nitrate reduction, Pigment production and growth rate (Kent and Kubica, 1985) .
Drug susceptibility testing (DST)
Drug susceptibility testing (DST) for first line and second line drugs was performed by absolute concentration method (MIC) for all drugs. Drug susceptibility testing (DST) against Isoniazid, Rifampicin, Ethambutol, Streptomycin and Kanamycin was performed by the proportional method on Lowenstein-Jensen (LJ) media at a concentration of 0.2, 40, 20, 4.0 and 20 µg/ml, respectively. Drug susceptibility testing (DST) against second line drugs (Capreomycin 10 µg/ml, Amikacin 4.0 µg/ml, Ofloxacin 2 µg/ml, Para-aminosalicylic acid 5.0 µg/ml, Ethionamide 20 µg/ml and Cycloserin 30 µg/ml) was performed using 2 critical proportions of 1 and 10% (World Health Organization, 2001; Ryoken, 2002) . Drugs were procured from Sigma (USA) and for each batch of DST a sensitive strain of H37Rv was used as a control. Table 5 . Both of two XDR-TB patients had pulmonary diseases and these patients were to have positive sputum smear test results. One of the XDR-TB patients (male, 45 years) with positive HIV infection had a definite history of previous treatment for TB and he Two cases of XDR-TB were detected Table 1 .Thus the frequency of XDR-TB among MDR-TB patients was 7.7%. No comparisons could be made although note that one was HIV positive.
Definition of XDR-TB
DISCUSSION
We found a low incidence of resistance to second-line drugs including XDR-TB (7.7%). In this study, we have estimated the incidence and not the prevalence of XDR-TB. An estimate of prevalence can be made by multiplying incidence by the average duration of the disease (World Health Organization, 2008) . Our study population is not representative of TB patients in Iran due to selection bias and selective testing bias. For this reason, we do not report a prevalence rate of XDR-TB. By July 2010, 58 countries and territories had reported at least one case of extensively drug-resistance TB (XDR-TB) (World Health Organization, 2008). There have been only a few reports of XDR-TB published from Iran. The first report that describes the transmission of XDR-TB among patients with secondary cases of TB, Masjedi et al. (2006) showed that 12(10.9%) of 113 Iranian MDR-TB strains were resistant to all 8 second-line drugs tested.
In further studies, Velayati et al. (2009) recognized that, of 146 MDR-TB strains 8 XDR isolates (5.4%) were identified. In addition, population-based data on drug susceptibility of TB isolates were obtained from the United States (1993 ( -2004 ( ), Latvia (2000 ( -2002 and South Korea (2004) , where 4, 19 and 15% of MDR-TB cases, respectively, were XDR (Wkly Rep, 2006) . Results of a hospital-based study in Japan and Russia were identified a high proportion of the XDR-TB strains 31% and 21%, respectively (Yoshiro et al., 2010; Punga et al., 2009 ).
These rates are not similar to our findings. The discrepancy in findings between the present and an earlier study (Wkly Rep, 2006; Yoshiro et al., 2010; Punga et al., 2009) can be explained by the difference in the numbers of MDR-TB cases. Our study has a small underlying population of MDR-TB cases. Using MDR-TB cases tested for second-line drugs as denominator is problematic in survey settings where the number of MDR-TB cases detected in the nationwide survey sample may be small and may not reflect the true proportion of XDR-TB among all MDR-TB cases (World Health Organization, 2008) . In addition, only a single fluroquinolones and two injectable agents were tested. Thus, XDR patients infected with strains resistant to fluroquinolone or injectable agents other than those tested could be misclassified as MDR or drug-susceptible TB (Balaji et al., 2010) . Due to our retrospective design, some of the variables examined were inconsistently recorded or missing. Second line drug susceptibility testing is not well standardized (Balaji et al., 2010) , so we cannot refer to a standard laboratory method to certify our fluroquinolone or injectable susceptibility results. Additionally, there is the insufficient quality assurance of drug susceptibility testing for second-line drugs (World Health Organization, 2008) . However, existing tests for susceptibility to second line drugs are less reproducible than tests for susceptibility to isoniazid and rifampicin, and better methods are needed (Heifets and Cangelosi, 1999) .
Another interesting observation was that one of the patients with XDR-TB was HIV co-infected in the present study that he died. Our data suggests no association between HIV infection and drug resistance.
Although outbreaks of drug resistant forms of tuberculosis among HIV infected patients have been widely documented in nosocomial and other congregate settings (Edlin et al., 1992; Moro et al., 1998) , our data suggests no association between HIV infection and drug resistance. Furthermore, little information is available about the association of the HIV and drug resistant TB on a population level (Kenyon et al., 1999; Mac-Arthur et al., 2001) .
In conclusion, we do not give an indication of XDR-TB rates in Iran. Because, the findings in this report are subject to at least two limitations. First, second line drug testing methods and results have varied because of the lack of international standards and the limited reproducibility of drug-susceptibility testing for certain drugs (World Health Organization, 2006c) . Second, our data were drawn from a convenience sample of isolates and might reflect a referral bias. Regardless, these data indicate Hadizadeh et al. 3799 that XDR-TB is geographically widespread. However, this should be interpreted with caution. Moreover, although our sample size of drug resistant isolates is small, most of the data available from our study reveal a low proportion of XDR-TB among MDR-TB cases. Data from this study indicate that XDR-TB is widespread in the majority of countries that reported were low TB burden countries or very few cases of MDR. This study highlights the need to strengthen capacity for both diagnosis and surveillance of resistance to second-line-drugs and XDR-TB.
